ARPA-H's $160M THRIVE Bet: Blueprint Promise Versus Bespoke Therapy's Persistent Execution Gap

Persistently underserved populations include pediatric patients, adults with late-presenting conditions, and fetal cases — as reflected in the Genomic Medicine Center Karolinska Rare Diseases (GMCK-RD) 10-year analysis of 15,644 individuals with suspected rare diseases, comprising 48% pediatric, 48% adult, and 4% fetal samples.

Diagnostic gaps remain substantial: the GMCK-RD initiative achieved an overall diagnostic yield of only 22.6%, providing a confirmed diagnosis for 3,538 individuals with variants across 1,570 genes — underscoring the large proportion of patients who remain undiagnosed despite advanced genomic sequencing.

Adolescent and young adult (AYA) oncology patients represent a specifically targeted population, addressed through initiatives such as the STRONG AYA project, which recognizes cancer in this demographic as a distinct rare disease challenge.

Drug development faces structural barriers unique to rare genetic conditions, including poorly understood disease natural history, small and phenotypically heterogeneous patient populations, diversified genotypes within a single disorder, and a lack of validated surrogate endpoints to substantiate clinical benefit.

Access and infrastructure deficits compound the unmet need: patients frequently encounter delays in obtaining accurate diagnoses and face barriers to treatment due to limited rare disease clinical expertise and fragmented care infrastructure.

Community-level prioritization has identified 23 rare diseases curated by the medical community based on unmet need and prevalence, providing a framework for directing research and therapeutic investment.

Genetic etiology optimization remains critical, as rare diseases are commonly attributable to genetic alterations — necessitating continued refinement of molecular technologies to identify pertinent genes and pathways underlying diverse disease phenotypes.

Gene therapy and editing platforms remain the most active frontier, with lentiviral gene addition achieving transfusion independence in β-thalassaemia and meaningful reductions in vaso-occlusive events in sickle cell disease, while CRISPR/Cas9-mediated disruption of BCL11A regulatory elements led to the first approved CRISPR-based therapy for haemoglobinopathies; vector design refinements and delivery platform improvements are extending this reach to retinal, cardiovascular, and gastrointestinal indications.

Emerging base editing and RNA therapeutics — including antisense oligonucleotides (ASOs), siRNAs, circular RNAs (circRNAs), self-amplifying mRNAs (saRNAs), and ADAR-directed base editors — are advancing through clinical evaluation, with extrahepatic delivery enabled by GalNAc conjugation, ligand-targeted lipid nanoparticles (LNPs), and engineered exosomes broadening applicability across neurological, metabolic, and rare monogenic disorders.

iPSC- and organoid-based disease modelling, integrated with diverse CRISPR modalities (knock-out, knock-in, CRISPRa/i, and genome-scale screening), is accelerating mechanistic characterisation of disease phenotypes and the identification of actionable therapeutic targets across oncological, neurodegenerative, inflammatory, and monogenic conditions.

Haploidentical haematopoietic stem cell transplantation (haplo-HSCT) is increasingly applied to rare haematological, metabolic, and immunological disorders, with ex vivo TCRαβ/CD19 depletion and unmanipulated protocols — including the G-CSF/ATG-based Beijing protocol and the PTCy-based Baltimore protocol — achieving survival outcomes comparable to matched sibling donor transplantation.

AI and machine learning, combined with multi-omics integration of genomic, transcriptomic, and epigenomic datasets, are enabling discovery of novel disease-relevant targets — including SARM1, OPHN1, and BPTF in sporadic ALS — while next-generation genome sequencing, with a reported diagnostic yield of 22.6% across 15,644 individuals, is identifying causal variants spanning SNVs, INDELs, repeat expansions, structural variants, and mobile element insertions.

Drug repurposing and cell-based therapeutic strategies continue to yield breakthrough treatments for conditions previously lacking any therapeutic option, with fetal haemoglobin (HbF) induction representing a particularly successful example of repurposed mechanistic insight translating into clinical benefit for haemoglobinopathies.

Limited clinical expertise and diagnostic infrastructure create significant barriers to patient identification and access to care; in regions such as Africa, these gaps are particularly acute, with additional challenges including sample integrity issues, referral gaps, and logistical delays that further impede timely diagnosis.

Data scarcity in drug discovery poses a fundamental constraint, especially in the absence of tractable biophysical assays and validated in vivo models; while advances in multi-omics have enabled collection of higher-dimensional data, limited sample sizes remain an enduring methodological challenge.

Genomic interpretability remains incomplete, as large-scale sequencing has generated a substantial volume of variants of uncertain significance — underscoring that a comprehensive understanding of genomic variation and its association with human disease is still a distant goal.

Administrative and financial barriers complicate the implementation of individualized treatment trials, requiring careful consideration of payor support structures, strategic operational factors, historic funding models, and relevant ethical frameworks.

Patent-based literature is frequently overlooked as an information source in rare disease drug discovery, due to complexities in access and analysis — representing an underutilized evidence base that could inform therapeutic development.

Complex ethical, legal, and social implications (ELSI) accompany the expansion of newborn screening programs for rare disorders, adding a layer of regulatory and societal deliberation to an already resource-constrained landscape.

Conventional therapeutic platforms face biological limitations, most notably the restricted CNS efficacy of standard enzyme replacement therapies (ERT) due to blood-brain barrier impermeability — a critical gap for neurologically manifesting rare genetic conditions.